TY - JOUR
T1 - Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia
AU - Chokshi, R.
AU - Restrepo, M. I.
AU - Weeratunge, N.
AU - Frei, C. R.
AU - Anzueto, A.
AU - Mortensen, E. M.
N1 - Funding Information:
Acknowledgments Dr. Mortensen was supported by a Department of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant and a Howard Hughes Medical Institute faculty start-up grant 00378-001. None of the authors, except for Drs. Anzueto, Restrepo, and Frei, have any conflicts of interest to disclose regarding this paper. Dr. Anzueto is currently a consultant with Pfizer, Ortho-McNeil, Sanofi-Aventis, Boehringer Ingelheim, GlaxoSmithKline, and Bayer Pharma. Dr. Anzueto has received research grants from Boehringer Ingelheim, GlaxoSmithKline, and C.R. Bard. Dr. Restrepo is a speaker for Pfizer, Wyeth and Elan Pharmaceuticals. Dr. Frei has received research grants from AstraZeneca and Elan Pharmaceuticals.
PY - 2007/7
Y1 - 2007/7
N2 - The purpose of this study was to examine the impact of antimicrobial monotherapy vs combination therapy on length of stay and mortality for patients with Streptococcus pneumoniae pneumonia. Thirty-nine percent of patients received monotherapy, while 61% received combination therapy. Although there was no significant difference in mortality (OR 1.25, 95% CI = 0.25-6.8), there was a significant increase in length of stay for patients who received combination therapy (p = 0.02). Patients with bacteremic pneumococcal pneumonia treated with empiric combination therapy had no significant difference in mortality; however, they did have increased length of stay after adjusting for severity of illness. Randomized controlled trials are needed to determine what is the optimal empiric antimicrobial regime for patients with community-acquired pneumonia.
AB - The purpose of this study was to examine the impact of antimicrobial monotherapy vs combination therapy on length of stay and mortality for patients with Streptococcus pneumoniae pneumonia. Thirty-nine percent of patients received monotherapy, while 61% received combination therapy. Although there was no significant difference in mortality (OR 1.25, 95% CI = 0.25-6.8), there was a significant increase in length of stay for patients who received combination therapy (p = 0.02). Patients with bacteremic pneumococcal pneumonia treated with empiric combination therapy had no significant difference in mortality; however, they did have increased length of stay after adjusting for severity of illness. Randomized controlled trials are needed to determine what is the optimal empiric antimicrobial regime for patients with community-acquired pneumonia.
UR - http://www.scopus.com/inward/record.url?scp=34347407788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347407788&partnerID=8YFLogxK
U2 - 10.1007/s10096-007-0307-3
DO - 10.1007/s10096-007-0307-3
M3 - Article
C2 - 17534677
AN - SCOPUS:34347407788
VL - 26
SP - 447
EP - 451
JO - European Journal of Clinical Microbiology and Infectious Diseases
JF - European Journal of Clinical Microbiology and Infectious Diseases
SN - 0934-9723
IS - 7
ER -